Results of Biogen's Alzheimer's Trial Drives Down Shares by 5%

Fierce Biotech reports that the results of Biogen’s (NASDAQ:BIIB) Phase 1 clinical trial of Alzheimer’s drug aducanumab had a negative impact on share prices.
According to the article:

Biogen’s 6-mg dose of its closely watched Alzheimer’s drug aducanumab failed to deliver what the Big Biotech and anxious analysts were hoping to see, falling short of clinical significance on two key measures of efficacy that would have pointed toward a clear path ahead in a pivotal study. And the safety data on the drug also worsened, with a heightened indication of toxicity that could spell trouble for this drug’s future.

Click here to read the full article on Fierce Biotech.